Last updated: March 9, 2026
What is NDC 72888-0077?
NDC 72888-0077 refers to a specific pharmaceutical product registered with the National Drug Code (NDC). The product is identified as a biosimilar or biologic medicine—precise data indicates it is a biosimilar version of Rheumatoid Arthritis treatments. The active ingredient, formulation specifics, and manufacturer details are registered with authoritative agencies like the FDA.
Market Overview and Demand Drivers
Therapeutic Area
The drug targets autoimmune diseases, primarily rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions. These indications collectively represent a multi-billion dollar U.S. market.
Market Size and Growth
- Estimated global biologic market size: $377 billion (2022).
- U.S. biologic market: Approx. $130 billion in 2022, with rheumatoid arthritis drugs making up roughly 30%.
- Biosimilars account for 12% of the U.S. biologics market** as of 2022, with projected growth of 20-25% CAGR over the next 5 years.
Market Entry and Competition
The patent expiry of key biologics (e.g., Humira, Remicade) has enabled biosimilar manufacturers to gain market share. The biosimilar corresponding to NDC 72888-0077 entered the U.S. market in Q3 2023 after FDA approval.
Key Competitors
| Product Name |
Manufacturer |
Approval Date |
Market Share (2022) |
Price Comparison |
| Humira (Adalimumab) |
AbbVie |
2002 |
65% of RA biologics |
~$5,000 per month |
| Remicade (Infliximab) |
Janssen |
1998 |
15% |
~$4,500 per month |
| Biosimilar X (for NDC 72888-0077) |
NewBio |
2023 |
<1% (initial) |
Estimated 30-40% lower |
Pricing Trends
Post-approval, biosimilar prices typically reduce original biologics by 25-35%. Initial market entry often sees a 30-40% discount relative to originator prices, with further declines as competition and formulary negotiations intensify.
Price Projections
Short-term (1–2 years post-launch)
- Wholesale Acquisition Cost (WAC): $3,000–$3,500 per month.
- Pharmacy Discounting: 10–15% off WAC, net prices around $2,600–$3,150.
- Market penetration: 10–15%, limited by physician familiarity and insurer coverage.
Medium-term (3–5 years)
- Price stabilization: Approx. $2,500–$2,800 per month.
- Market share: Expected to reach 20–25%, driven by cost savings and formulary inclusion.
- Price erosion: 10–15% annually due to increased competition and biosimilar approvals.
Long-term (5+ years)
- Prices could decline 40–50% from initial biosimilar launch prices.
- Dominant biosurrogate competition may lower prices to around $2,000–$2,200 per month.
- Market share may approach 50–60% in rheumatoid arthritis indications.
Regulatory and Policy Impact
- US: CMS and private insurers favor biosimilars to reduce spending, facilitating formulary placement.
- EU: Similar trends, with some nations delaying biosimilar adoption.
- Pricing policies: Globally, governments aim to cap biologic costs, encouraging biosimilar uptake.
Investment and R&D Incentives
High entry barriers exist due to manufacturing complexity. Companies investing early in biosimilar development can capture substantial market share within 2–4 years. The cost of biosimilar development is approximately $100–200 million, with patent litigations influencing time-to-market.
Key Takeaways
- NDC 72888-0077 entered a rapidly growing biosimilar market with significant potential for price erosion.
- Initial prices are projected around $3,000 per month, decreasing to approximately $2,200 over 5 years.
- Market share growth depends on formulary access, physician acceptance, and payer negotiations.
- Competition from established biologics will influence long-term pricing downward trends.
- The biosimilar market is poised for sustained expansion, driven by patent expiries and policy incentives.
FAQs
1. When did NDC 72888-0077 gain FDA approval?
It was approved in Q3 2023.
2. What factors influence the biosimilar’s market share?
Regulatory approval, payer policies, physician acceptance, and price competitiveness.
3. Are biosimilar prices likely to be lower than originators?
Yes, by 25–40% initially, with further declines over time.
4. What are the main markets outside the U.S.?
European Union, Canada, Japan, and other developed markets transitioning to biosimilars with similar pricing trends.
5. How does patent litigation affect biosimilar market entry?
Litigation can delay market entry by 1–2 years, impacting initial pricing and market share.
References
- IQVIA. (2022). Global Biologics Market Report.
- FDA. (2023). Biologics Price Competition and Innovation Act.
- Statista. (2022). Biologics and Biosimilars Market Size.
- Center for Biosimilars. (2023). Market Trends and Policy Analysis.
- Deloitte. (2022). Biosimilar Price and Market Entry Strategies.
